Assessment of knowledge regarding rational use of medicines among Interns of a Tertiary care Teaching Hospital

Authors

  • Dr Jayashree V Nagaral VN Assistant Professor, Department of Pharmacology, Hassan Institute of Medical Sciences, Hassan-573201, Karnataka., India
  • Dr Nalini GK Department of Pharmacology, Hassan Institute of Medical Sciences, Hassan-573201, Karnataka., India
  • Dr. Anusha J Department of Pharmacology, Hassan Institute of Medical Sciences, Hassan-573201, Karnataka., India
  • Dr Sahana GN Department of Pharmacology, Hassan Institute of Medical Sciences, Hassan-573201, Karnataka., India
  • Dr Deepak P Department of Pharmacology, Hassan Institute of Medical Sciences, Hassan-573201, Karnataka., India
  • Dr Bhavishya Anna Valder Department of Pharmacology, Hassan Institute of Medical Sciences, Hassan-573201, Karnataka., India
  • Dr Karthik V Department of Pharmacology, Hassan Institute of Medical Sciences, Hassan-573201, Karnataka., India

Keywords:

rational prescription, pharmacology

Abstract

Background : Irrational prescription of drugs leads to  the delay in relief, more adverse effects, prolonged hospitalization, increased morbidity and mortality, the emergence of antibiotic  resistance, economical loss to patient and community. This study was undertaken  in order to assess  the basic knowledge regarding  rational use of medicines among medical interns.

Methodology: This questionnaire based observation study was conducted among fresh interns  of a tertiary care teaching hospital, Karnataka. A prevalidated questionnaire comprising 14 questions on rational use of medicines was distributed.The data was analysed and expressed as percentage  of resposes.

Results: . Majority of participants grade their prescribing knowledge as good (67%).Most of the interns agreed as UG training was adequate to prepare them to prescribe rationally and safely. 60% felt that safety is the most important aspect while  prescribing a drug.80% suggested the integration of UG pharmacology with clinical subjects.

Conclusion: The study found that large number of participants were aware of essential medicine. Hence, assessing knowledge of RUM among interns would be helpful in promoting RUM and improving health care services. 

Downloads

Download data is not yet available.

References

Qaseem, A., Barry, M.J., Kansagara, D., Amer Coll, P. Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the American college of physicians. Ann. Intern. Med. 2016; 164 (5): 350.

Ferguson JM. SSRI Antidepressant Medications: Adverse Effects and Tolerability. Prim Care Companion J Clin Psychiatry. 2001; 3(1):22-27.

Bauer M. Pfennig A., Severus E., Whybrow P.C. Angst J. Moller H. J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J. Biol. Psychiatry 14. 2013; 334-385.

Ashton, A.K., Jamerson, B.D., Weinstein L.W, Wagoner, C. Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr. Ther. Res. Clin. Exp. 2005; 66, 96–106.

Bora, E., Harrison, B.J., Yucel, M., Pantelis, C. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychological medicine 43. 2013; 2017-2026.

Baune BT, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study. J Affect Disord. 2018; 229:421-428.

American Psychiatric Association, 2013. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. DSM-5. American Psychiatric Publishing, Washington DC

Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhnog H, Nielsen SM, Hogg S, Mørk A, Stensbøl TB. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (LuAA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011; 54:3206–3221.

Levada OA, Troyan AS. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram. J Affect Disord [Internet]. 2019; 250:114–22.

Vieta E, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram. J Affect Disord [Internet]. 2018; 227:803–9.

Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl). 2015; 232(12):2061–70.

Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder. Psychiatry Clin Neurosci. 2020; 74(2):140–8.

Baune BT, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study. J Affect Disord. 2018; 229:421-428.

Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharmacol Ther [Internet]. 2015; 145:43–57.

Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004; 161,826–835.

Fink, K. B., & Gothert, M. 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev. 2007; 59,360–417.

Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr. 2014; 19(2):121–33.

Downloads

Published

2022-04-30

Issue

Vol. 12 No. 4 (2022): Apr

Section

Research Articles

License

Copyright (c) 2022 International Journal of Pharmacological Research

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
    4. Author must Submit Copyright form  After acceptance of Article

How to Cite

1.
VN DJVN, GK DN, Dr. Anusha J, GN DS, P DD, Anna Valder DB, et al. Assessment of knowledge regarding rational use of medicines among Interns of a Tertiary care Teaching Hospital. Int J of Pharmc Res [Internet]. 2022 Apr. 30 [cited 2025 Mar. 14];12(4):e5736. Available from: https://ssjournals.co.in/index.php/ijpr/article/view/5736